Zoetis Inc. (ZTS) Announces Earnings Results
Zoetis Inc. (NYSE:ZTS) posted its quarterly earnings data on Thursday. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02, Bloomberg Earnings reports. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.52 EPS. Zoetis updated its FY17 guidance to $2.34-$2.39 EPS.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be issued a dividend of $0.105 per share. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a yield of 0.62%. Zoetis’s dividend payout ratio (DPR) is presently 23.73%.
ZTS has been the subject of several analyst reports. Cowen and Company set a $60.00 target price on shares of Zoetis and gave the company a “buy” rating in a research report on Tuesday, July 11th. Deutsche Bank AG restated a “buy” rating and issued a $65.00 target price (up from $62.00) on shares of Zoetis in a research report on Monday, July 17th. Stifel Nicolaus restated a “buy” rating and issued a $65.00 target price on shares of Zoetis in a research report on Friday, July 21st. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $62.00 target price on shares of Zoetis in a research report on Monday, August 7th. Finally, Cantor Fitzgerald set a $75.00 target price on shares of Zoetis and gave the company a “buy” rating in a research report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $65.76.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.